commentary nhs patients should have a choice of drug for wet age related macular degeneration despite pressure from pharma

Commissioners have to pay more than lip service to the obligation on us to find cost effective treatment options. That bevacizumab is as clinically effective and safe as aflibercept and ranibizumab—which patients will continue to be offered as alternatives—has been shown comprehensively.1 We intend to share information with patients through accessible media (including leaflets and...